Abstract
Background:Everolimus is a mammalian target of rapamycin inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC.Methods:Ninety-seven patients with mRCC were treated with everolimus till April 2013 in our institutions. Patients were stratified in two groups with NLR >3 (Group A) vs
Original language | English |
---|---|
Pages (from-to) | 1755-1759 |
Number of pages | 5 |
Journal | British Journal of Cancer |
Volume | 109 |
Issue number | 7 |
DOIs | |
Publication status | Published - Oct 1 2013 |
Keywords
- everolimus
- mTOR inhibitors
- neutrophil-tolymphocyte ratio
- renal cell carcinoma
- targeted therapy
- tyrosine kinase inhibitor
ASJC Scopus subject areas
- Cancer Research
- Oncology